SEARCH

SEARCH BY CITATION

References

  • 1
    Druker BJ,O'Brien SG,Cortes J,Radich J. Chronic myelogenous leukemia. Hematology Am Soc Hematol Educ Program 2002: 11135.
  • 2
    Sattler M,Griffin JD. Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol 2003; 40: 410.
  • 3
    Steelman LS,Pohnert SC,Shelton JG,Franklin RA,Bertrand FE,McCubrey JA. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 2004; 18: 189218.
  • 4
    Lugo TG,Pendergast AM,Muller AJ,Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990; 247: 107982.
  • 5
    Daley GQ,Van Etten RA,Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990; 247: 82430.
  • 6
    Druker BJ,Tamura S,Buchdunger E,Ohno S,Segal GM,Fanning S,Zimmermann J,Lydon NB. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 5616.
  • 7
    Le Coutre P,Mologni L,Cleris L,Marchesi E,Buchdunger E,Giardini R,Formelli F,Gambacorti-Passerini C. In vivo eradication of human Bcr-Abl-positive leukemia cells with an Abl kinase inhibitor. J Natl Cancer Inst 1999; 91: 1638.
  • 8
    Kantarjian HM,O'Brien S,Cortes J,Giles FJ,Rios MB,Shan J,Faderl S,Garcia-Manero G,Ferrajoli A,Verstovsek S,Wierda W,Keating M, et al. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. Cancer 2003; 98: 263642.
  • 9
    Sawyers CL,Hochhaus A,Feldman E,Goldman JM,Miller CB,Ottmann OG,Schiffer CA,Talpaz M,Guilhot F,Deininger MW,Fischer T,O'Brien SG, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 35309.
  • 10
    Hochhaus A,Hughes T. Clinical resistance to imatinib: mechanisms and implications. Hematol Oncol Clin North Am 2004; 18: 64156, ix.
  • 11
    Daub H,Specht K,Ullrich A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nat Rev Drug Discov 2004; 3: 100110.
  • 12
    Hughes TP,Kaeda J,Branford S,Rudzki Z,Hochhaus A,Hensley ML,Gathmann I,Bolton AE,van Hoomissen IC,Goldman JM,Radich JP. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 142332.
  • 13
    Graham SM,Jorgensen HG,Allan E,Pearson C,Alcorn MJ,Richmond L,Holyoake TL. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 31925.
  • 14
    Sawyers CL. Calculated resistance in cancer. Nat Med 2005; 11: 8245.
  • 15
    Karin M,Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5: 74959.
  • 16
    Hayden MS,Ghosh S. Signaling to NF-kappaB. Genes Dev 2004; 18: 2195224.
  • 17
    Karin M,Cao Y,Greten FR,Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002; 2: 30110.
  • 18
    Staudt LM. The molecular and cellular origins of Hodgkin's disease. J Exp Med 2000; 191: 20712.
  • 19
    Kordes U,Krappmann D,Heissmeyer V,Ludwig WD,Scheidereit C. Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia 2000; 14: 399402.
  • 20
    Guzman ML,Neering SJ,Upchurch D,Grimes B,Howard DS,Rizzieri DA,Luger SM,Jordan CT. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001; 98: 23017.
  • 21
    Kirchner D,Duyster J,Ottmann O,Schmid RM,Bergmann L,Munzert G. Mechanisms of Bcr-Abl-mediated NF-kappaB/Rel activation. Exp Hematol 2003; 31: 50411.
  • 22
    Frelin C,Imbert V,Griessinger E,Loubat A,Dreano M,Peyron JF. AS602868, a pharmacological inhibitor of IKK2, reveals the apoptotic potential of TNF-alpha in Jurkat leukemic cells. Oncogene 2003; 22: 818794.
  • 23
    Frelin C,Imbert V,Griessinger E,Peyron A,Rochet N,Philip P,Dageville C,Sirvent A,Hummelsberger M,Berard E,Dreano E,Sirvent N, et al. Targeting NF-{kappa}B activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells. Blood 2005; 105: 80411.
  • 24
    Tipping AJ,Baluch S,Barnes DJ,Veach DR,Clarkson BM,Bornmann WG,Mahon FX,Goldman JM,Melo JV. Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate. Leukemia 2004; 18: 13526.
  • 25
    le Coutre P,Tassi E,Varella-Garcia M,Barni R,Mologni L,Cabrita G,Marchesi E,Supino R,Gambacorti-Passerini C. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000; 95: 175866.
  • 26
    Imbert V,Rupec RA,Livolsi A,Pahl HL,Traenckner EB,Mueller-Dieckmann C,Farahifar D,Rossi B,Auberger P,Baeuerle PA,Peyron JF. Tyrosine phosphorylation of I kappa B-alpha activates NF-kappa B without proteolytic degradation of I kappa B-alpha. Cell 1996; 86: 78798.
  • 27
    Griessinger E,Frelin C,Cuburu N,Imbert V,Dageville C,Hummelsberger M,Sirvent N,Dreano M,Peyron JF. Preclinical targeting of NF-kappaB and FLT3 pathways in AML cells. Leukemia 2008; 22: 14669.
  • 28
    Mercurio F,Zhu H,Murray BW,Shevchenko A,Bennett BL,Li J,Young DB,Barbosa M,Mann M,Manning A,Rao A. IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science 1997; 278: 8606.
  • 29
    He Y,Wertheim JA,Xu L,Miller JP,Karnell FG,Choi JK,Ren R,Pear WS. The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl. Blood 2002; 99: 295768.
  • 30
    Duncan EA,Goetz CA,Stein SJ,Mayo KJ,Skaggs BJ,Ziegelbauer K,Sawyers CL,Baldwin AS. IkappaB kinase beta inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells Mol Cancer Ther 2008; 7: 3917.
  • 31
    Reuther JY,Reuther GW,Cortez D,Pendergast AM,Baldwin AS,Jr. A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev 1998; 12: 96881.
  • 32
    Cilloni D,Messa F,Arruga F,Defilippi I,Morotti A,Messa E,Carturan S,Giugliano E,Pautasso M,Bracco E,Rosso V,Sen A, et al. The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance. Leukemia 2006; 20: 617.
  • 33
    O'Hare T,Corbin AS,Druker BJ. Targeted CML therapy: controlling drug resistance, seeking cure. Curr Opin Genet Dev 2006; 16: 929.
  • 34
    Quintás-Cardama A,Cortes J. Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. Clin Cancer Res 2008; 14: 4292399.
  • 35
    Hoover RR,Mahon FX,Melo JV,Daley GQ. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood 2002; 100: 106871.
  • 36
    Mohi MG,Boulton C,Gu TL,Sternberg DW,Neuberg D,Griffin JD,Gilliland DG,Neel BG. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci USA 2004; 101: 31305.
  • 37
    Baumgartner B,Weber M,Quirling M,Fischer C,Page S,Adam M,Von Schilling C,Waterhouse C,Schmid C,Neumeier D,Brand K. Increased IkappaB kinase activity is associated with activated NF-kappaB in acute myeloid blasts. Leukemia 2002; 16: 206271.
  • 38
    Shah NP. Loss of response to imatinib: mechanisms and management. Hematology Am Soc Hematol Educ Program 2005: 1837.
  • 39
    Bhatia R,Holtz M,Niu N,Gray R,Snyder DS,Sawyers CL,Arber DA,Slovak ML,Forman SJ. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003; 101: 47017.
  • 40
    O'Hare T,Eide CA,Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007; 110: 22429.
  • 41
    Nicolini FE,Corm S,Le QH,Sorel N,Hayette S,Bories D,Leguay T,Roy L,Giraudier S,Tulliez M,Facon T,Mahon FX, et al. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia 2006; 20: 10616.
  • 42
    Shah NP,Tran C,Lee FY,Chen P,Norris D,Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399401.
  • 43
    O'Hare T,Walters DK,Stoffregen EP,Jia T,Manley PW,Mestan J,Cowan-Jacob SW,Lee FY,Heinrich MC,Deininger MW,Druker BJ. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005; 65: 45005.